기업 프로필 · Healthcare

IQVIA Holdings Inc

IQV · 미국
거래소
미국
국가 / 지역
USA
상장일
2013년 5월 9일
직원 수
93,000
웹사이트
www.iqvia.com
현재가
$167.77
실시간 · 2026년 6월 18일
적정 매수가
≤ $155
안전마진 진입가
베일리 성장 점수
45/100
다소 약함
내재가치 · 3단계 구간 현재가 $167.77 실시간 · 보수적 구간과 적정 구간 사이

종합 밸류에이션 구간 · 보수적 $145–$165 / 적정 $180–$220 / 낙관적 $235–$285. $167.77 기준, 보수적 구간과 적정 구간 사이.

보고서 발행 시 $165.62(2026년 5월 28일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

시가총액US$288.6억
매출 (TTM)US$166.32억
EBITDAUS$30.01억
순이익률8.33%
ROE22.49%
PER (TTM)21.51
선행 PER14.01
PEG0.72
EPSUS$8.04
52주 범위US$153.01 – US$247.05
애널리스트 목표주가US$226.95
애널리스트 평가4.3 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.